Table 3.

Cox proportional hazards models examining association of KRAS mutation status with DFS in 2,478 patients with BRAF–wild-type colon cancer

UnivariateMultivariatea
KRAS statusN (events)3-year DFS rate (95% CI)HR (95% CI)PHR (95% CI)P
Model 1
 Any codon 12 mutation779 (256)68% (64%–71%)1.50 (1.28–1.76)<0.00011.52 (1.28–1.80)<0.0001
 Codon 13 mutation220 (71)67% (60%–73%)1.46 (1.13–1.89)0.00351.36 (1.04–1.77)0.0248
 Wild typeb1,479 (360)77% (75%–80%)ReferenceReference
Model 2
 Individual codon 12 mutations
  c.35G>A (p.G12D)378 (122)68% (63%–73%)1.51 (1.23–1.85)<0.00011.53 (1.23–1.89)0.0001
  c.35G>T (p.G12V)213 (68)70% (63%–76%)1.38 (1.07–1.79)0.01451.40 (1.07–1.82)0.0139
  c.34G>T (p.G12C)82 (30)61% (50%–73%)1.66 (1.14–2.41)0.00781.63 (1.11–2.41)0.0128
  c.35G>C (p.G12A)49 (19)63% (49%–77%)1.78 (1.12–2.82)0.01481.75 (1.10–2.79)0.0178
  c.34G>A (p.G12S)52 (14)72% (59%–85%)1.28 (0.75–2.19)0.36241.37 (0.80–2.35)0.2485
  c.34G>C (p.G12R)5 (3)50% (1%–99%)3.81 (1.23–11.87)0.02095.30 (1.69–16.64)0.0043
 Codon 13 mutation
  c.38G>A (p.G13D)220 (71)67% (60%–73%)1.46 (1.13–1.89)0.00351.36 (1.04–1.77)0.0246
 Wild typeb1,479 (360)77% (75%–80%)ReferenceReference
  • aAdjusted for age, gender, T stage, N stage, number of examined nodes, grade, performance status, tumor site, mismatch repair status, treatment.

  • bKRAS and BRAF wild type.